Comparison · NCT02625974-sae
Nifurtimox 60-day Regimen vs Nifurtimox 30-day Regimen: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nifurtimox 60-day Regimen vs Nifurtimox 30-day Regimen: serious adverse events. Trial comparisons, record NCT02625974-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02625974-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0274 | 0.0126 | 0.0585 | wilson | |
| Risk in group 2 | 0.027 | 0.00923 | 0.0765 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00037 | -0.0512 | 0.0362 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.258 | 3.98 | log | |
| Odds ratio, group 1 over group 2 | 1.01 | 0.249 | 4.13 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Nifurtimox 60-day Regimen than on Nifurtimox 30-day Regimen | 2,700 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nifurtimox 60-day Regimen | Nifurtimox daily dose 8-10 mg/kg (adolescents, 40-60 kg) or 10-20 mg/kg (infants/children, below 40 kg) for 60 days | 6 | 219 | EG000 |
| Group 2 | Nifurtimox 30-day Regimen | Nifurtimox daily dose 8-10 mg/kg (adolescents, 40-60 kg) or 10-20 mg/kg (infants/children, below 40 kg) for 30 days followed by placebo | 3 | 111 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Part 1: From first application of study drug up to and including 7 days after last application of study drug Part 2: first occurred or worsened at start of study part 2 up to 3 years.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
- NCT number
- NCT02625974
- Phases
- PHASE3
- Conditions
- Chagas Disease
- Interventions
- Nifurtimox (Lampit, BAYA2502), Placebo
- Lead sponsor
- Bayer
- Results first posted
- 2019-10-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02625974?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02625974-sae